Beam Therapeutics Inc. ( BEAM ) was founded by David Liu, J. Keith Joung, and Feng Zhang in 2017. Its headquarters and research hub are in Cambridge, MA, while its manufacturing hub is in Durham, NC. It is one ofI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating we ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this t ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology Q4 2025 financial results call and webcast. At this time, all par ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Speaker5Greetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the cal ...

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University (FSU) College of Medicine, further drivi ...

Acrivon Therapeutics (NasdaqGM:ACRV) 2026 Conference February 27, 2026 08:00 AM ET Company ParticipantsAdam Levy - CFO and Head of Investor RelationsBrian Slomovitz - Co-Chair of the Cervical Cancer CommitteeDomenica Lorusso - GOG-Foundation/ENGOT LiaisonMansoor Raza Mirza - CMOPeter Blume-Jensen - CEO, President, and Co-founderRamez N. Eskander - Ovarian Portfolio LeadRobert L. Coleman - CSOAdam LevyGood morning, everyone, and welcome to today's webcast. My name is Adam Levy, and I'm Chief Financial Office ...

Caris Life Sciences Inc. (NASDAQ:CAI) on Thursday posted better-than-expected fourth-quarter earnings.Caris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents. Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million."Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on thi ...

Argenx SE (NASDAQ:ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).Argenx reported fourth-quarter earnings of $8.02 per share, beating the consensus of $6.02. Sales jumped from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion.“Argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, CEO of Argenx ...

Argenx SE (NASDAQ:ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).Argenx reported fourth-quarter earnings of $8.02 per share, beating the consensus of $6.02. Sales jumped from $761.2 million to $1.32 billion, surpassing the consensus estimate of $1.29 billion.“Argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, CEO of Argenx ...